Cue Biopharma

Cue Biopharma is a clinical-stage biopharmaceutical company developing a new class of immunotherapies for the treatment of cancer and other serious diseases. Their approach focuses on harnessing the natural signals, or "cues," of the immune system to selectively activate tumor-specific T cells directly in the patient's body. This targeted approach aims to provide a more effective response while preserving safety, by restoring the capacity of the patient's own immune system to fight disease.

Cue Biopharma's pipeline includes multiple product candidates based on their Immuno-STAT™ platform, which is designed to selectively activate the patient's immune system without the need for ex vivo manipulation. Their lead clinical candidate, CUE-101, has shown promising results in clinical trials for the treatment of head and neck cancer. Beyond oncology, Cue Biopharma is also exploring the potential of their platform technology for the treatment of infectious and autoimmune diseases.

Cue Biopharma is dedicated to developing a new class of cancer immunotherapies that mimic the natural signals of the immune system. Their mission is to expand the reach of immunotherapy and improve therapeutic benefit by delivering targeted therapies designed to be more effective and better tolerated, ultimately restoring the patient's own immune system to fight cancer.

Cue Biopharma fosters a collaborative and innovative culture that values scientific excellence and a commitment to improving patients' lives. They prioritize a high-science approach, attracting and developing a world-class team of experts dedicated to advancing their research and clinical development programs. Their focus on patient-centric therapies creates a passionate and driven environment where employees are empowered to contribute to a groundbreaking mission.

Cue Biopharma is committed to fostering a diverse, equitable, and inclusive workplace where all employees feel valued, respected, and empowered to contribute their unique talents. They aim to create a culture that embraces and celebrates diversity of thought, background, and experience, believing that this will drive innovation and enhance their ability to develop groundbreaking therapies for patients.